David Slack
Chief Executive Officer bij Cend Therapeutics, Inc.
Vermogen: 64 403 $ op 31-03-2024
Profiel
David Slack is currently the President, Chief Executive Officer & Director at Cend Therapeutics, Inc. He is also the Chairman at Lisata Therapeutics Australia Pty Ltd.
Previously, he held positions such as Director-Technology Alliances & Licensing at Aventis Pharmaceuticals, Inc. and Rhone-Poulenc Rorer Pharmaceuticals, Inc. He was also the Vice President-Business Development at Ionis Pharmaceuticals, Inc. and the Chief Business Officer at Viracta Subsidiary, Inc. Additionally, he worked as a Principal at DS Lifescience Consulting.
Mr. Slack's education includes an undergraduate degree from California State University-Sacramento and an MBA from Monterey Institute of International Studies.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 17-04-2023 | 20 642 ( 0.25% ) | 64 403 $ | 31-03-2024 |
Actieve functies van David Slack
| Bedrijven | Functie | Begin |
|---|---|---|
Cend Therapeutics, Inc.
 Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Chief Executive Officer | 08-07-2020 |
| Lisata Therapeutics Australia Pty Ltd. | Chairman | - |
Eerdere bekende functies van David Slack
| Bedrijven | Functie | Einde |
|---|---|---|
| LISATA THERAPEUTICS, INC. | President | 01-05-2023 |
| DS Lifescience Consulting | Corporate Officer/Principal | 01-03-2021 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Corporate Officer/Principal | 01-07-2020 |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-01-2004 |
| Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Corporate Officer/Principal | 01-01-2000 |
Opleiding van David Slack
| California State University-Sacramento | Undergraduate Degree |
| Monterey Institute of International Studies | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
| Rhone-Poulenc Rorer Pharmaceuticals, Inc. | |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
Cend Therapeutics, Inc.
Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Health Technology |
| Lisata Therapeutics, Inc. | |
| Lisata Therapeutics Australia Pty Ltd. | |
| DS Lifescience Consulting |
